Nicholas Jacobus

In today's Pharmaceutical Executive Daily, Kardigan sets terms for a $350 million IPO that would value the cardiovascular biotech at approximately $1.3 billion, Pharmaceutical Executive speaks with Rick Winningham on building the next generation of leaders behind the pipeline, and Jazz Pharmaceuticals reports that the Phase III Lagoon trial of Zepzelca failed to meet its primary endpoint of overall survival in second-line small cell lung cancer.

Jazz Pharmaceuticals' Zepzelca failed to improve overall survival in the Phase III Lagoon confirmatory trial for second-line small cell lung cancer, putting its accelerated approval in that setting at risk.

Fresh off the HBA's Honorable Mentor award, Rick Winningham, CEO of Theravance Biopharma, reflects on a career defined by cultivating the cultures driving the science.

Kardigan has filed to raise approximately $350 million in an IPO that would value the cardiovascular biotech at roughly $1.3 billion, expecting that its three late-stage programs can attract investors in a market still riding a biotech IPO wave.

In today's Pharmaceutical Executive Daily, Bruce Liu examines China's latest policy guidance establishing premium pricing and priority reimbursement access for truly innovative drugs, Parabilis Medicines surges more than 45 percent on its first day of trading on Nasdaq, and Pharmaceutical Executive speaks with Eli Lilly's Sarah O'Keeffe, Group Vice President of Product Research and Development, on how the company's $4.5 billion Medicine Foundry is designed to transform the discovery-to-production handoff and accelerate speed to patient.

Parabilis Medicines surged 58% on its first trading day, pushing its market cap to roughly $3.7 billion and cementing its $670 million raise as the largest biotech IPO on record.

In today's Pharmaceutical Executive Daily, Parabilis Medicines prices a record-breaking $670 million IPO, Swedish biotech AlzeCure Pharma enters a collaboration and out-licensing agreement with Eli Lilly for its Alzheimer's candidate, and FDA approves an every-eight-week maintenance dosing regimen for Eli Lilly's Ebglyss.

AlzeCure Pharma has licensed Alzheimer's candidate ACD680 to Eli Lilly in a deal worth potentially more than $1 billion, adding an oral gamma-secretase modulator that targets amyloid production upstream to Lilly's Alzheimer's portfolio.

Parabilis Medicines raises $670 million in an above-range IPO, plus $75 million in a concurrent Regeneron private placement, to advance its Helicon peptide platform targeting proteins.

In this episode, Ron Lanton draws on insights from the JP Morgan Healthcare Conference to explain how healthcare investment is shifting from backing novel ideas to funding organizations that can scale, survive regulatory and reimbursement pressure, and embed technology into the operational infrastructure of care delivery.

In today's Pharmaceutical Executive Daily, a pharma funding roundup covers two RNA-focused biotechs that secured fresh capital, GSK announces a $10.6 billion agreement to acquire Nuvalent in its largest deal in over a decade, , and Pharmaceutical Executive speaks with David Coman, CEO of BGBx, on why the firm's rebranding from BGB reflects a broader shift in how biopharma commercialization now demands integrated consulting, communications, and scientific frameworks.

City Therapeutics closed a $99.5 million Series B to push two RNAi programs into the clinic this year while Eloxx Pharmaceuticals raised $66 million alongside a Nasdaq uplisting to advance its nonsense mutation readthrough platform.

GSK has agreed to acquire Nuvalent in a deal that secures two next-generation NSCLC inhibitors under active FDA review with potential year-end launches.

With more than $43 billion committed in five months, the pharma industry isn't just licensing from China, it's restructuring where global drug discovery begins.

David Coman, CEO, BGBx, explains how the firm's rebranding reflects a broader shift in biopharma commercialization, where integrating consulting, communications, and a three-dimensional science framework is increasingly necessary for companies.

In today's Pharmaceutical Executive Daily, Roche and Nurix Therapeutics announce a global collaboration, a pharma M&A roundup covers three deals announced today, and Pharmaceutical Executive contributors examine how an emerging wave of biologics is signaling a new treatment era in alopecia areata beyond the established JAK inhibitor class.

Incyte, Galmed Pharmaceuticals, and Johnson & Johnson each announced acquisitions this week, with deals spanning a $2 billion bet on a Phase III bleeding disorder antibody, a GI medtech pivot, and a $1 billion move into KRAS-targeting degrader conjugates as dealmaking across therapeutic categories continues.

Roche has struck an exclusive collaboration with Nurix Therapeutics to co-develop BTK degrader bexobrutideg, paying over $700 million upfront in a deal that could top $3 billion in total.

In today's Pharmaceutical Executive Daily, the Supreme Court unanimously rules in favor of Hikma Pharmaceuticals in its patent dispute with Amarin over Vascepa, Pfizer licenses Chai Discovery's generative AI platform, and C.K. Wang argues that high-quality real-world data represents the most promising path forward for closing persistent gaps in ovarian cancer care.

The Supreme Court ruled unanimously in favor of Hikma Pharmaceuticals, finding its generic Vascepa did not infringe Amarin's patents under the skinny-label pathway, a decision that strengthens legal protections for generic manufacturers.

Chai Discovery has licensed its generative AI drug discovery platform to Pfizer, giving the company early access to its next-generation Chai-3 model and a custom model trained on Pfizer's own data.

In today's Pharmaceutical Executive Daily, Eli Lilly escalates its 340B enforcement standoff by notifying covered entities of a five-business-day window to submit required claims data or lose access to 340B pricing, Alnylam Pharmaceuticals and Inceptive Nucleics announce a three-year strategic AI collaboration worth up to $2 billion, and Anne Marie Robertson of Eversana speaks on the trends shaping the future of oncology commercialization following ASCO 2026.

Alnylam Pharmaceuticals has partnered with Inceptive to apply generative AI to siRNA design, pairing Inceptive's biology-trained models with Alnylam's two decades of proprietary RNAi data to accelerate candidate discovery.

In today's Pharmaceutical Executive Daily, Cam Olig of Prescryptive Health touches on the results of a new market access survey, Eli Lilly and Ascidian Therapeutics announce a global research collaboration worth up to $1.9 billion to develop RNA exon editors for inherited kidney diseases, and the FDA issues new draft guidance to reduce the submission burden for gene therapy developers.

Eli Lilly moves to deny 340B discounts to hospitals refusing to submit claims data under its documentation policy, escalating a months-long standoff with the American Hospital Association and prompting calls for federal intervention.

Ascidian Therapeutics has entered a global research and licensing deal with Eli Lilly to develop RNA exon-editing therapies for monogenic kidney diseases, a class of genetic conditions with an unmet need for treatment.

In today's Pharmaceutical Executive Daily, FDA has accepted a new drug application for giredestrant under priority review, FDA also issues a complete response letter for Cingulate's CTx-1301, and Dan Troy, former FDA Chief Counsel, explains the roadblocks and hurdles facing the FDA's efforts to bring stricter oversight to direct-to-consumer prescription drug advertising.

FDA has accepted Roche's NDA for giredestrant under Priority Review, moving the investigational oral SERD closer to potential approval .

FDA has issued a Complete Response Letter to Cingulate’s ADHD candidate CTx-1301 over manufacturing-related deficiencies, delaying approval of the once-daily therapy while leaving its clinical safety and efficacy profile unchallenged.

In today's Pharmaceutical Executive Daily, the FDA approves Shionogi's Xocova, a pharma M&A roundup covers Servier's acquisition of Edgewise Therapeutics' muscular dystrophy, Eli Lilly's licensing of Hanmi's long-acting GLP-2 therapy, and the merger of Rallybio and Avenzo Therapeutics, finally Sean Werner examines why breakthrough cell and gene therapies continue to fail at the regulatory finish line.